Meeting
2023 ASCO Annual Meeting
Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study.
Authors
Junjie Li
Shanghai Cancer Center, Shanghai, China
Junjie Li , Wenya Wu , Yunsong Yang , Wentao Yang , Shao Zhimin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 528)
DOI
10.1200/JCO.2023.41.16_suppl.528
Abstract #
528
Poster Bd #
358
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Analysis of disease-free survival in CheckMate 274 by PD-L1 combined positive score and tumor proportion score.
First Author: Matt D. Galsky
Poster
2019 ASCO Annual Meeting
PD-L1/PD-1 expression as a predictor of response to BCG in patients with high-risk non–muscle invasive bladder cancer.
First Author: Mathieu Roumiguie
Poster
2018 ASCO Annual Meeting
Tumor infiltrating lymphocytes to predict DFS from intense dose-dense (idd) EPC regimen: Results from the German Adjuvant Intergroup Node-positive study (GAIN-1).
First Author: Aurelia Noske
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Correlation of lung cancer mutational profile with immune profile.
First Author: Antonios Papanicolau-Sengos